PMID- 10220297
OWN - NLM
STAT- MEDLINE
DCOM- 19990607
LR  - 20190915
IS  - 1073-2322 (Print)
IS  - 1073-2322 (Linking)
VI  - 11
IP  - 4
DP  - 1999 Apr
TI  - Evaluation of Fc-receptor positive (FcR+) and negative (FcR-) monocyte subsets in 
      sepsis.
PG  - 229-34
AB  - The monocyte/macrophage (Mphi is central in the regulation of the immune response 
      in states of trauma and sepsis. Because monocyte subsets, characterized by 
      expression of the Fc-receptor (FcR), were shown to play distinct immunologic 
      roles in trauma, it was the objective of this study to assess insights into the 
      functional role of FcR positive (FcR+) and negative (FcR-) subclasses in surgical 
      sepsis. In a prospective study, peripheral blood Mphi from 20 septic patients and 
      10 healthy volunteers were evaluated on consecutive days after the onset of 
      sepsis. FcR+/- subsets were separated by rosetting with antibody-coated human 
      erythrocytes. Receptor expression and synthesis of proinflammatory cytokines were 
      used to evaluate the functional role of these cells. We demonstrated a 
      significant monocytosis (350%; p<.01) and suppression of human lymphocyte antigen 
      (HLA-DR) expression (35%; p<.05). Synthesis of Interleukin-1beta (IL-1beta; e.g., 
      Day 1: 230+/-30 pg/mL) and Interleukin-6 (IL-6; e.g., Day 1: 1920+/-350 U/mL) 
      were significantly higher (p<.05) in FcR+ subsets than in controls (IL-1beta: 
      100+/-5 pg/mL; IL-6: 353+/-75 U/mL). Tumor necrosis factor-alpha (TNF-alpha) was 
      elevated in FcR+ monocytes but did not reach a significant value. Interleukin-8 
      (IL-8) synthesis showed only on Day 1 and in controls significant differences in 
      FcR+ and FcR- cells (Day1: FcR-: 19.6+/-4.1 nM; FcR+: 9+/-4.3 nM). Sepsis results 
      in a significant shift toward FcR+ monocytes. This cell population is 
      characterized by high proinflammatory cytokine synthesis. The extent of this 
      shift seems to identify a group of high risk septic patients that might benefit 
      from immunomodulatory therapy.
FAU - Schinkel, C
AU  - Schinkel C
AD  - Ludwig-Maximilians University Munich, Klinikum Grosshadern, Department of 
      Surgery, Germany.
FAU - Sendtner, R
AU  - Sendtner R
FAU - Zimmer, S
AU  - Zimmer S
FAU - Walz, A
AU  - Walz A
FAU - Hultner, L
AU  - Hultner L
FAU - Faist, E
AU  - Faist E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Receptors, Fc)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - HLA-DR Antigens/metabolism
MH  - Humans
MH  - Inflammation/metabolism
MH  - Interleukin-1/metabolism
MH  - Interleukin-6/metabolism
MH  - Interleukin-8/metabolism
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*metabolism
MH  - Predictive Value of Tests
MH  - Receptors, Fc/*metabolism
MH  - Sepsis/*metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 1999/04/29 00:00
MHDA- 1999/04/29 00:01
CRDT- 1999/04/29 00:00
PHST- 1999/04/29 00:00 [pubmed]
PHST- 1999/04/29 00:01 [medline]
PHST- 1999/04/29 00:00 [entrez]
AID - 10.1097/00024382-199904000-00001 [doi]
PST - ppublish
SO  - Shock. 1999 Apr;11(4):229-34. doi: 10.1097/00024382-199904000-00001.